Trials / Completed
CompletedNCT01928472
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 402 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | H7N9c low dose with adjuvant | |
| BIOLOGICAL | H7N9c medium dose with adjuvant | |
| BIOLOGICAL | H7N9c high dose with adjuvant | |
| BIOLOGICAL | H7N9c high dose without adjuvant |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-08-26
- Last updated
- 2019-06-11
- Results posted
- 2015-05-21
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01928472. Inclusion in this directory is not an endorsement.